NO995901L - Vektor - Google Patents

Vektor

Info

Publication number
NO995901L
NO995901L NO995901A NO995901A NO995901L NO 995901 L NO995901 L NO 995901L NO 995901 A NO995901 A NO 995901A NO 995901 A NO995901 A NO 995901A NO 995901 L NO995901 L NO 995901L
Authority
NO
Norway
Prior art keywords
vector
noi
poi
tumour
interest
Prior art date
Application number
NO995901A
Other languages
English (en)
Norwegian (no)
Other versions
NO995901D0 (no
Inventor
Susan Mary Kingsman
Christopher Robert Bebbington
Fiona Margaret Ellard
Miles William Carroll
Kevin Alan Myers
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO995901(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9711579.4A external-priority patent/GB9711579D0/en
Priority claimed from GBGB9713150.2A external-priority patent/GB9713150D0/en
Priority claimed from GBGB9714230.1A external-priority patent/GB9714230D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of NO995901D0 publication Critical patent/NO995901D0/no
Publication of NO995901L publication Critical patent/NO995901L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
NO995901A 1997-06-04 1999-12-02 Vektor NO995901L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9711579.4A GB9711579D0 (en) 1997-06-04 1997-06-04 Therapeutic genes
GBGB9713150.2A GB9713150D0 (en) 1997-06-20 1997-06-20 Fusion proteins
GBGB9714230.1A GB9714230D0 (en) 1997-07-04 1997-07-04 Therapeutic genes
PCT/GB1998/001627 WO1998055607A2 (en) 1997-06-04 1998-06-04 Tumor targeted vector

Publications (2)

Publication Number Publication Date
NO995901D0 NO995901D0 (no) 1999-12-02
NO995901L true NO995901L (no) 2000-02-04

Family

ID=27268875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995901A NO995901L (no) 1997-06-04 1999-12-02 Vektor

Country Status (16)

Country Link
US (6) US6852703B1 (zh)
EP (2) EP1717248A1 (zh)
JP (3) JP2002507117A (zh)
CN (1) CN1224712C (zh)
AT (1) ATE444358T1 (zh)
AU (1) AU747602B2 (zh)
CA (1) CA2292760A1 (zh)
CY (1) CY1109686T1 (zh)
DE (1) DE69841204D1 (zh)
DK (1) DK1012259T3 (zh)
ES (1) ES2332435T3 (zh)
IL (1) IL132596A0 (zh)
NO (1) NO995901L (zh)
NZ (1) NZ500633A (zh)
PT (1) PT1012259E (zh)
WO (1) WO1998055607A2 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO1998055607A2 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
DE60040555D1 (de) * 1999-11-18 2008-11-27 Oxford Biomedica Ltd Küle
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
IL160132A0 (en) * 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
NZ532060A (en) 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
AU2002337885B1 (en) * 2001-10-16 2003-04-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7939059B2 (en) * 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
MXPA05001933A (es) * 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
AU2003241006B2 (en) 2003-05-21 2011-03-24 Ares Trading S.A. TNF-like secreted protein
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
TW200616662A (en) * 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
PL1994055T3 (pl) 2006-03-10 2015-02-27 Wyeth Llc Przeciwciała anty-5T4 i ich zastosowanie
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
CA2661848C (en) 2006-09-01 2015-02-03 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
KR20090069330A (ko) * 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
EP2313784B1 (en) * 2008-07-15 2015-02-18 Oxford BioMedica (UK) Limited Immunotherapeutic method
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2459224T3 (en) * 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
US9265969B2 (en) * 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
MX361058B (es) 2012-01-24 2018-11-23 Pfizer Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
CA2924684C (en) 2013-09-18 2021-02-09 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
JP2018510627A (ja) 2015-03-10 2018-04-19 レイデン ユニバーシティ メディカル センター メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
JP2018532801A (ja) * 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
AU2016343809B2 (en) 2015-10-30 2022-08-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
KR20180083868A (ko) 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
CN108148905A (zh) * 2018-02-13 2018-06-12 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一段可作为抑郁症标记物的序列
CN111886024B (zh) 2018-03-08 2024-07-30 凡恩世制药(北京)有限公司 抗tip-1抗体及其用途
AU2019233523A1 (en) 2018-03-12 2020-10-01 Genmab A/S Antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
AU3353989A (en) * 1988-03-04 1989-09-22 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
JPH04500308A (ja) 1989-05-17 1992-01-23 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 組換え型生成物のレトロウィルス媒介分泌
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
WO1992000092A1 (en) 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
EP0621338A3 (en) 1993-04-21 1997-10-29 Ajinomoto Kk The interleukin-2 response blocking immunosuppressor.
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5439654A (en) 1994-03-10 1995-08-08 Steris Corporation Cutter for opening sterilant reagent cups
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
AU3635695A (en) 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
GB9423085D0 (en) * 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
EP0857217B1 (en) 1995-10-16 2005-04-13 Dana-Farber Cancer Institute Novel expression vectors and methods of use
AU7719596A (en) * 1995-11-07 1997-05-29 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
CA2237000A1 (en) 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
DE19724502C1 (de) 1997-06-11 1998-10-08 Webasto Thermosysteme Gmbh Heizgerät
ATE350474T1 (de) 1998-08-10 2007-01-15 Agensys Inc Bpc-1: ein ausgeschiedenes gehirnspezifisches protein das von prostata- und blasen-krebszellen exprimiert und ausgeschieden wird
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
DE60040555D1 (de) 1999-11-18 2008-11-27 Oxford Biomedica Ltd Küle

Also Published As

Publication number Publication date
EP1717248A1 (en) 2006-11-02
US20030018004A1 (en) 2003-01-23
JP2011000122A (ja) 2011-01-06
NO995901D0 (no) 1999-12-02
US8084249B2 (en) 2011-12-27
US7531648B2 (en) 2009-05-12
JP2002507117A (ja) 2002-03-05
AU7780198A (en) 1998-12-21
CA2292760A1 (en) 1998-12-10
PT1012259E (pt) 2009-11-06
WO1998055607A2 (en) 1998-12-10
WO1998055607A3 (en) 1999-03-04
AU747602B2 (en) 2002-05-16
US20090017532A1 (en) 2009-01-15
CN1258319A (zh) 2000-06-28
EP1012259B1 (en) 2009-09-30
JP2009153524A (ja) 2009-07-16
NZ500633A (en) 2002-10-25
US20110065173A1 (en) 2011-03-17
DE69841204D1 (de) 2009-11-12
CN1224712C (zh) 2005-10-26
US20060286634A1 (en) 2006-12-21
US20050032216A1 (en) 2005-02-10
IL132596A0 (en) 2001-03-19
CY1109686T1 (el) 2014-08-13
ES2332435T3 (es) 2010-02-04
ATE444358T1 (de) 2009-10-15
DK1012259T3 (da) 2010-01-18
EP1012259A2 (en) 2000-06-28
US6852703B1 (en) 2005-02-08
US7718627B2 (en) 2010-05-18

Similar Documents

Publication Publication Date Title
NO995901D0 (no) Vektor
DE69415163D1 (de) ZUZAMMENSETUNG ENTHALTEND 1,1,1,2,3,4,4,5,5,5,-DECAFLUORPENTAN UND n-PROPANOL
PL309403A1 (en) Modified cutinases, dna, vector and host
NL194084B (nl) Roeten alsmede rubbersamenstellingen met dergelijke roeten.
DE69940785D1 (de) Proteinexpressionsvektor und benutzung desselbigen
EP0571442A4 (en) CYTOKIN INDUCIBLE PROTEIN TSG-14, ITS ENCODING DNA AND THEIR USE.
HU9503194D0 (en) Novel sunsscreens, photoprotective cosmetic compositions containing them and uses thereof
Lee et al. Some properties of the generalization of the Fibonacci sequence
EP0237045A3 (en) Dna encoding flagellin and vector having the same
DE69630300D1 (en) Operationshandschuhe aus neoprencopolymeren
NZ237198A (en) Zymogen form of protein c, dna, vector and use as a pharmaceutical
EP0273800A3 (en) Hirudine variants, their use and preparation
EP0363436A4 (en) CLONED GENES OF PROTEIN G VARIANTS AND PROTEIN G VARIANTS EXPRESSED BY THESE GENES.
FR2714074B1 (fr) Promoteurs des gènes GRA1, GRA2, GRA5 et GRA6 de toxoplasma gondii et vecteurs d'expression comprenant lesdits promoteurs.
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
EP0287084A3 (en) Alcohols containing 2-methyl or 2-methoxyphenyl groups, and their use as flavouring agents
AU119245S (en) Decorator's hand tool
FR2677996B1 (fr) Vecteurs de clonage et/ou d'expression preparation et utilisation.
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
HU9402646D0 (en) Anomere fluoro-ribosyl-amines
GB9710636D0 (en) Novel mixture
GB9604518D0 (en) Novel compounds
Ito Studies on the processing of the exported proteins in Bacillus subtilis
Raghavachary Fracture generation on arbitrary surfaces using Voronoi polygons
Pepper The effects of goal specificity, goal difficulty and goal source on endurance performance

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application